Last reviewed · How we verify

NCT04494035: AVATR

AVATR - Arteriovenous Access Thrombosis Removal With CAPERE Thrombectomy System

Terminated NA Last updated 13 September 2022
What this trial tests

NA trial testing CAPERE Thrombectomy System in Arteriovenous Graft Thrombosis in 7 participants. Terminated before completion.

Timeline
14 January 2020
Primary endpoint
23 October 2020
23 October 2020

Quick facts

Lead sponsorMedtronic Endovascular
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposedevice feasibility
Enrollment7
Start date14 January 2020
Primary completion23 October 2020
Estimated completion23 October 2020
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Medtronic Endovascular — full company profile →

Who can join

18 and older, any sex, with Arteriovenous Graft Thrombosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective, single-arm, non-blinded study, intending to treat and collect and evaluate data in up to ten (10) human subjects who are currently being treated with hemodialysis and who present with acute thrombosis in their arteriovenous (AV) grafts, treated with the CAPERE® Thrombectomy System.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of CAPERE Thrombectomy System

Trials testing the same drug.

Other Medtronic Endovascular trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04494035.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing